Remove

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

Application Number		10623010	
Filing Date		2003-07-18	
First Named Inventor Danie		el Plastina	
Art Unit		2173	
Examiner Name	John Cabeca		
Attorney Docket Number		MS#303012 1/MSFT 5055	

	S.S. ALLITO										
Examiner Cite Patent Number		Patent Number	Kind Code ¹ Issue Date		Name of Patentee or Applicant Rele		Releva	ages,Columns,Lines where elevant Passages or Relevan gures Appear			
	1	6418421	B1	2002-0	7-09	Hurtado et al.					
	2	6549922	B1	2003-0	4-15	Srivastava et	al.				
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		_
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		_
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Patentee or Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear			
	1	20040064500	A1	2004-0	4-01	Kolar et al.					
	2	20030225777	A1	2003-1	2-04	Marsh					
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	please click the Ad	d button			_
				FOREIG	IN PAT	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²			Publication Date Name of Patentee Applicant of cited Document		e or	where Rele	or Relevant	Τ,
	1										

U.S.PATENTS

If you wish	h to a	additional Foreign Patent Document citation information please click the Add button Add
		NON-PATENT LITERATURE DOCUMENTS Remove
Examiner Initials*	Cite No	nclude name of the author (in CAPITAL LETTERS), itile of the article (when appropriate), tile of the item book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s). To sublisher, city and/or country where published.
	1	
If you wis	h to a	additional non-patent literature document citation information please click the Add button Add
		EXAMINER SIGNATURE
Examiner	Signa	re Date Considered
SEVAMIN	ED: In	all if reference considered upother or not election is in conference with MDED 600. Draw the through a

1 See Kind Codes of USPTO Patent Documents at yeary_USPTO_GOV or MPEP 901.6.2 Extens office that issued the document, by the ho-other code (WIPD Standard ST.3.) 27% plaquese petited coduments, by mandation of the year of the Emperor compute protect the sear-all number of the Patend document.

1 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 9 Applicant is to place a check mark here if English language transition in attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10623010		
Filing Date		2003-07-18		
First Named Inventor	Daniel Plastina			
Art Unit		2173		
Examiner Name	John	John Cabeca		
Attorney Docket Number		MS#303012.1/MSFT 5055		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to n	nake the appropriate:	selection(s):
---------------	----------	---------------	-----------------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(e)(1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_					
Signature	/Robert O. Enyard Jr./	Date (YYYY-MM-DD)	2006-07-05		
Name/Print	Robert O. Envard Jr.	Registration Number	57780		

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, and Superiment of Commence, P. 0. Bot 1450, Alexandria, V.32.511.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, V.32.311.450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.